Dr. Rachel P. Rosovsky, MD

Dr. Rosovsky practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Rosovsky's NPI, 1821072257, was assigned on November 30, 2005. Dr. Rosovsky graduated from Harvard Medical School in 2000. Dr. Rosovsky holds Massachusetts license 217573.

Dr. Rosovsky's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Rosovsky's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Rosovsky is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Rosovsky to 3 more hospitals, 2 medical groups and 1 community health center, each named with a free account. Dr. Rosovsky's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosovsky practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rosovsky's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rosovsky is board certified in hematology by the American Board of Internal Medicine. Dr. Rosovsky is licensed in Massachusetts.

Dmand AI lists arterial blot clot /embolism, chronic anemia, chronic embolism thrombosis, deep vein thrombosis (DVT) and lung cancer among the conditions Dr. Rosovsky treats.

CMS data shows 683 Medicare services from Dr. Rosovsky across 9 procedure codes in 2024, for 261 Medicare patients. Medicare paid $51,409 for them.

CMS counts 261 Medicare patients who saw Dr. Rosovsky in 2024. The largest group is 65 to 74, with 118 patients. 72% of them have high blood pressure, and 72% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosovsky's median patient age at 73, with 57% women.

In 2024, Dr. Rosovsky wrote 392 Medicare Part D claims for 112 patients. 14% of them were for generic drugs. CMS names the drug for 355 of them, across 4 drugs with 11 or more claims each, at $469,227 in total drug cost. In 2023, CMS named 296 claims across 5 drugs.

Dr. Rosovsky accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosovsky as offering telehealth.

Dmand AI links 137 papers to Dr. Rosovsky, published from 2008 to 2025. 2020 was the busiest year, with 21. The most frequent topics are Pulmonary Embolism, Venous Thromboembolism and Anticoagulants. Dr. Rosovsky has published most often in Res Pract Thromb Haemost. Dr. Rosovsky's most frequent co-authors are Christopher Kabrhel, MD, Kenneth Rosenfield, MD and Hanny Toban Al-Samkari, MD.

Dmand AI links Dr. Rosovsky to 5 clinical trials, 3 of them phase 2 studies. Conditions studied include Ovarian Neoplasms, Pulmonary Embolism and Small Cell Lung Carcinoma. Massachusetts General Hospital sponsors the most, 3.

CMS Open Payments shows 191 general payments to Dr. Rosovsky from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 49% of the total. Penumbra, Inc. paid the most, $64,094.

Dr. Rosovsky graduated from Harvard Medical School in 2000. Dr. Rosovsky is a member of AHA, ASH and Pulmonary Embolism Response Team (PERT) Consortium.

Dr. Rosovsky is in network with 17 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.